Skip to main content
SpringerLink
Log in

Chemoprevention of Oesophageal Cancer and the AspECT Trial

  • Conference paper
Cancer Prevention II

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 181))

Abstract

Oesophageal cancer is on the rise and often present in an advanced state. Advances in surgical techniques, chemotherapy and radiotherapy have not changed the prognosis of oesophageal cancer over the last 20 years. With the unravelling of molecular biology of carcino-genesis in the oesophagus, there is a need for a paradigm shift from cancer treatment to prevention. Barrett's oesophagus is the commonest pre-malignant condition for development of oesophageal adenocarcinomas and is eminently suitable for the study of chemoprevention strategies. Now in its third year, the AspECT trial is the biggest, multicentre, randomised controlled clinical trial looking at the long-term chemopre-vention effect of esomeprazole with or without aspirin. More than 85% of the participants tolerated the medications at the initial intended doses, and the drop-out rate has been 7%; the interim analysis is due in 2011.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Abdalla SI, Sanderson IR, Fitzgerald RC (2005) Effect of inflammation on cyclooxygenase (COX)-2 expression in benign and malignant oesophageal cells. Carcinogenesis 26:1627–1633

    Article  PubMed  CAS  Google Scholar 

  • Alikhan M, Rex D, Khan A, Rahmani E, Cummings O, Ulbright TM (1999) Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest Endosc 50:23–26

    Article  PubMed  CAS  Google Scholar 

  • Avidan B, Sonnenberg A, Schnell TG, Chejfec G, Metz A, Sontag SJ (2002) Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol 97:1930–1936

    Article  PubMed  Google Scholar 

  • Bani-Hani K, Sue-Ling H, Johnston D, Axon AT, Martin IG (2000) Barrett's oesophagus: results from a 13-year surveillance programme. Eur J Gastroenterol Hepatol 12:649–654

    Article  PubMed  CAS  Google Scholar 

  • Boyer J, Laugier R, Chemali M, Arpurt J P, Boustière C, Canard JM, Dalbies PA, Gay G, Escourrou J, Napoléon B, Palazzo L, Ponchon T, Richard-Mollard B, Sautereau D, Tucat G, Vedrenne B; French Society of Digestive Endoscopy SFED (2007) French Society of Digestive Endoscopy SFED guideline: monitoring of patients with Barrett's esophagus. Endoscopy 39:840–842

    Article  PubMed  CAS  Google Scholar 

  • Buttar NS, Wang KK, Sebo TJ, Riehle DM, Krishnadath KK, Lutzke LS, Anderson MA, Petterson TM, Burgart LJ (2001) Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 120:1630–1639

    Article  PubMed  CAS  Google Scholar 

  • Cameron AJ, Ott BJ, Payne WS (1985) The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 313:857–859

    PubMed  CAS  Google Scholar 

  • Conio M, Blanchi S, Lapertosa G, Ferraris R, Sablich R, Marchi S, D'Onofrio V, Lacchin T, Iaquinto G, Missale G, Ravelli P, Cestari R, Benedetti G, Macrì G, Fiocca R, Munizzi F, Filiberti R (2003) Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol 98:1931–1939

    Article  PubMed  Google Scholar 

  • Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA (2002) Surveillance and survival in Barrett'sadenocarcinomas: a population-based study. Gastroenterology 122:633–640

    Article  PubMed  Google Scholar 

  • Corley DA, Kerlikowske K, Verma R, Buffler P (2003) Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 124:47–56

    Article  PubMed  CAS  Google Scholar 

  • Das D, Ishaq S, Harrison R, Kosuri K, Harper E, Decaestecker J, Sampliner R, Attwood S, Barr H, Watson P, Moayyedi P, Jankowski J (2008) Management of Barrett's esophagus in the UK: overtreated and underbiopsied but improved by the introduction of a national randomized trial. Am J Gastroenterol 103:1079–1089

    Article  PubMed  Google Scholar 

  • Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM (2002) Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology 122:26–33

    Article  PubMed  Google Scholar 

  • El-Serag HB, Aguirre T V, Davis S, Kuebeler M, Bhattacharyya A, Sampliner RE (2004) Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 99:1877–1883

    Article  PubMed  CAS  Google Scholar 

  • Eloubeidi MA, Mason AC, Desmond RA, El-Serag HB (2003) Temporal trends (1973–1997) in survival of patients with esophageal adenocarci-noma in the United States: a glimmer of hope?. Am J Gastroenterol 98:1627–1633

    PubMed  Google Scholar 

  • Fitzgerald RC, Omary MB, Triadafilopoulos G (1996) Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model. J Clin Invest 98:2120–2128

    Article  PubMed  CAS  Google Scholar 

  • Heath EI, Canto MI, Piantadosi S, Montgomery E, Weinstein WM, Herman JG, Dannenberg AJ, Yang V W, Shar AO, Hawk E, Forastiere AA (2007) Chemoprevention for Barrett's Esophagus Trial Research Group. Secondary chemopreven-tion of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 99:545–557

    Article  PubMed  CAS  Google Scholar 

  • Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC (2004) Proton pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 180:387–391

    PubMed  Google Scholar 

  • Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC (2008) Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus. Aliment Pharmacol Ther 27:321–336

    PubMed  CAS  Google Scholar 

  • Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N (2003) Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 138:176–186

    PubMed  Google Scholar 

  • Jankowski JA, Wright NA, Meltzer SJ, Triadafilopoulos G, Geboes K, Casson AG, Kerr D, Young LS (1999) Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol 154:965–973

    PubMed  CAS  Google Scholar 

  • Jankowski JA, Provenzale D, Moayyedi P (2002) Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the West (systematic review). Gastroenterology 122:588–590

    Article  PubMed  Google Scholar 

  • Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, Tarnawski AS (1999) Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 5:1418–1423

    Article  PubMed  CAS  Google Scholar 

  • Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, Lloyd D, Havu N, Frame MH, Romàn J, Walan A; Long-Term Study Group (2000) Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 118:661–669

    Article  PubMed  CAS  Google Scholar 

  • Lagergren J, Bergstrom R, Lindgren A, Nyrén O (1999) Symptomatic gastro-esophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340:825–831

    Article  PubMed  CAS  Google Scholar 

  • Moayyedi P, Burch N, Akhtar-Danesh N, Enaganti SK, Harrison R, Talley NJ, Jankowski J (2008) Mortality rates in patients with Barrett's oesophagus. Aliment Pharmacol Ther 27:316–320

    PubMed  CAS  Google Scholar 

  • Montgomery E, Goldblum JR, Greenson JK, Haber MM, Lamps LW, Lauwers GY, Lazenby AJ, Lewin DN, Robert ME, Washington K, Zahurak ML, Hart J (2001) Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol 32:379–388

    Article  PubMed  CAS  Google Scholar 

  • Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE (2001) Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarci-noma sequence. Am J Gastroenterol 96:990–996

    PubMed  CAS  Google Scholar 

  • Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G (1999) Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 117:327–335

    Article  PubMed  CAS  Google Scholar 

  • Peters FT, Ganesh S, Kuipers EJ, Sluiter WJ, Karrenbeld A, de Jager-Krikken A, Klinkenberg-Knol EC, Lamers CB, Kleibeuker JH (2000) Effect of elimination of acid reflux on epithelial cell proliferative activity of Barrett esophagus. Scand J Gastroenterol 35:1238–1244

    Article  PubMed  CAS  Google Scholar 

  • Peters JH, Clark G W, Ireland A P, Chandrasoma P, Smyrk TC, DeMeester TR (1994) Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 108:813–821

    PubMed  CAS  Google Scholar 

  • Pohl H, Welch HG (2005) The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinomas incidence. J Natl Cancer Inst 97:142–146

    PubMed  Google Scholar 

  • Provenzale D, Schmitt C, Wong JB (1999) Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 94:2043–2053

    Article  PubMed  CAS  Google Scholar 

  • Ragunath K, Krasner N, Raman VS, Haqqani MT, Phillips CJ, Cheung I (2005) Endoscopic abla tion of dysplastic Barrett's oesophagus compar ing argon plasma coagulation and photodynamic therapy: a randomized prospective trial assessing efficacy and cost-effectiveness. Scand J Gastroenterol 40:750–758

    Article  PubMed  Google Scholar 

  • Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS (2000) Is there publication bias in the reporting of cancer risk in Barrett's esophagus?. Gastroenterology 119:333–338

    Article  PubMed  CAS  Google Scholar 

  • Sharma P, Falk G W, Weston A P, Reker D, Johnston M, Sampliner RE (2006) Dysplasia and cancer in a large multicentre cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 4:566–572

    Article  PubMed  Google Scholar 

  • Solaymani-Dodaran M, Logan R F, West J, Card T (2005) Mortality associated with Barrett's esophagus and gastroesophageal reflux disease diagnoses—a population-based cohort study. Am J Gastroenterol 100:2616–2621

    Article  PubMed  Google Scholar 

  • Souza RF, Shewmake K, Terada LS, Spechler SJ (2002) Acid exposure activates the mitogen-acti-vated protein kinase pathways in Barrett's esophagus. Gastroenterology 122:299–307

    Article  PubMed  CAS  Google Scholar 

  • Spechler SJ, Robbins AH, Rubins HB, Vincent ME, Heeren T, Doos WG, Colton T, Schimmel EM (1984) Adenocarcinoma and Barrett's esophagus. An overrated risk?. Gastroenterology 87: 927–933

    PubMed  CAS  Google Scholar 

  • Thomas T, Abrams KR, de Caestecker JS, Robinson RJ (2007) Meta analysis:cancer risk in Barrett's oesophagus. Aliment Pharmacol Ther 26:1465–1477

    Article  PubMed  CAS  Google Scholar 

  • Tsujii M, DuBois RN (1995) Alterations in cellular adhesion and apoptosis in epithelial cells overex-pressing prostaglandin endoperoxide synthase 2. Cell 83:493–501

    Article  PubMed  CAS  Google Scholar 

  • Tsujii M, Kawano S, DuBois RN (1997) Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94:3336–3340

    Article  PubMed  CAS  Google Scholar 

  • Umansky M, Yasui W, Hallak A, Brill S, Shapira I, Halpern Z, Hibshoosh H, Rattan J, Meltzer S, Tahara E, Arber N (2001) Proton pump inhibitors reduce cell cycle abnormalities in Barrett's esophagus. Oncogene 20:7987–7991

    Article  PubMed  CAS  Google Scholar 

  • Vaezi MF, Richter JE (1996) Role of acid and duodenogastroesophageal reflux in gastroeso-phageal reflux disease. Gastroenterology 111:1192–1199

    Article  PubMed  CAS  Google Scholar 

  • Vaughan TL, Dong LM, Blount PL, Ayub K, Odze RD, Sanchez CA, Rabinovitch PS, Reid BJ (2005) Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus:a prospective study. Lancet Oncol 6:945–952

    Article  PubMed  CAS  Google Scholar 

  • Wang KK, Sampliner RE (2008) Updated Guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 103:788–797

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Digestive Disease Centre Leicester Royal Infirmary Infirmary Sq. Leicester, LE1 5WW, UK

    Debasish Das

  2. Department of Gastroenterology Kettering General Hospital, Rothwell Road Kettering, Northants, Kettering, NN16 8UZ, UK

    Andrew P. Chilton

  3. James Black Senior Clinical Fellow Department of Clinical Pharmacology, University of Oxford, Radcliffe Infirmary Woodstock Road, Oxford, OX2 6HA, UK

    Janusz A. Jankowski

Authors
  1. Debasish Das
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew P. Chilton
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Janusz A. Jankowski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Janusz A. Jankowski .

Editor information

Editors and Affiliations

  1. Zentrum fücr Tumordiagnostik und Prävention, Rorschacherstr. 150, St. Gallen, 9006, Schweiz

    Hans-Jörg Senn , Ursula Kapp  & Florian Otto ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Das, D., Chilton, A.P., Jankowski, J.A. (2009). Chemoprevention of Oesophageal Cancer and the AspECT Trial. In: Senn, HJ., Kapp, U., Otto, F. (eds) Cancer Prevention II. Recent Results in Cancer Research, vol 181. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-69297-3_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-69297-3_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-69296-6

  • Online ISBN: 978-3-540-69297-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation